Announcements
Sidley Represents Hennessy Capital Investment Corp. VIII in Its US$241.5 Million IPO
February 6, 2026
Sidley represented Hennessy Capital Investment Corp. VIII (NASDAQ: HCICU), a special purpose acquisition company (SPAC), in its upsized US$241.5 million initial public offering (IPO). The SPAC is sponsored by an affiliate of Hennessy Capital Group LLC, a serial SPAC sponsor and long-time client of the firm. Hennessy Capital Investment Corp. VIII sold a total of 24.15 million units in the IPO, including 3.15 million units sold through the full exercise of the underwriters' over-allotment option. Hennessy Capital Investment Corp. VIII is focusing its search for a target business in the industrial technology and energy transition sectors. The IPO closed on February 6, 2026.
The Sidley team was led by Mike Heinz (Capital Markets), Jeffrey Smith and Jeff Wysong (M&A and Private Equity), and included Danielle N. Sismour, Jack N. Cadden, and Benjamin Bosmans-Verdonk (M&A and Private Equity); Katie Klaben and Yunzhou Wang (Capital Markets-Section 16); and Carla Teodoro (Investment Funds).
The Sidley team was led by Mike Heinz (Capital Markets), Jeffrey Smith and Jeff Wysong (M&A and Private Equity), and included Danielle N. Sismour, Jack N. Cadden, and Benjamin Bosmans-Verdonk (M&A and Private Equity); Katie Klaben and Yunzhou Wang (Capital Markets-Section 16); and Carla Teodoro (Investment Funds).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents HealthCare Royalty in Monetization Agreement for Modeyso Commercial RoyaltiesApril 24, 2026Sidley Represents Underwriters in Connection With National Healthcare Properties’ US$462 Million Public OfferingApril 23, 2026Sidley Represents Liberty Mutual in US$750 Million Senior Notes OfferingApril 23, 2026Sidley Represents Cboe Global Markets in Its US$300 Million Sale of Cboe Australia and Cboe Canada to TMX GroupApril 22, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026Sidley Represents Opus Genetics in US$155 Million Financing With Oberland CapitalApril 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory





